Every material Form 8-K CME filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
CME Group reported third-quarter 2025 results, with total revenue of $1,537.6 million, down from $1,584.4 million a year earlier, and net income of $908.0 million, down from $912.8 million. Diluted earnings per share were $2.49 versus $2.50, while adjusted diluted EPS was $2.68, flat with the prior year. The headline GAAP measures declined year over year, which matters to shareholders because lower trading activity reduced revenue.
Total revenue was $1,537.6 million for the quarter ended September 30, 2025, versus $1,584.4 million in the same quarter of 2024.
Diluted EPS was $2.49 on a GAAP basis versus $2.50 a year earlier; adjusted diluted EPS was $2.68, unchanged from the prior year.
Market data and information services revenue was a record $203 million; clearing and transaction fees were $1.2 billion.
Quarterly average daily volume was 25,322 thousand contracts, down from 28,289 thousand in the third quarter of 2024.
CME Group said its Chief Accounting Officer, Jack Tobin, has decided to retire after more than 23 years with the company and seven...
Jack Tobin notified CME Group of his retirement decision on September 9, 2025.
Tobin will remain Chief Accounting Officer until October 30, 2026.
Tobin has held the role since 2015; the company says the departure is voluntary and not due to any disagreement on accounting, operations, policies or practices.
CME Group will search for a successor, and Tobin will work with that person on the transition.
CME Group reported second-quarter 2025 revenue of $1.7 billion, up 10% from the same quarter in 2024, and record average daily volume of 30.2 million contracts, up 16%. Diluted earnings per share were $2.81 on a GAAP basis, compared with $2.42 a year earlier, and $2.96 on an adjusted basis, compared with $2.56.
Q2 2025 revenue of $1.7 billion versus $1.5 billion in Q2 2024; operating income of $1.1 billion
Diluted EPS of $2.81 (GAAP) versus $2.42; adjusted diluted EPS of $2.96 versus $2.56
Average daily volume of 30.2 million contracts, up 16%; Micros ADV of 4.1 million contracts
As of June 30, 2025: $2.2 billion in cash and $3.4 billion of debt; about $3.0 billion in dividends paid in the first six months
CME Group entered a new multi-currency revolving credit facility of $2.25 billion, which can be increased to $3.25 billion, maturing April 23, 2030. The company also amended its 364-day secured credit facility for its clearing house, set at $7 billion and eligible to rise to $10 billion, to provide temporary liquidity in specified scenarios. The filing describes the facilities as standard backup and working capital arrangements, and it does not disclose any drawn balances.
New senior revolving credit facility of $2.25 billion, expandable to $3.25 billion, effective April 23, 2025
Facility matures April 23, 2030 and can be prepaid without premium or penalty; proceeds are for working capital and general corporate purposes
Amendment No. 10 to the 364-day clearing house credit facility sets a $7 billion secured facility, eligible to rise to $10 billion
Both agreements require maintenance of minimum net worth or consolidated tangible net worth tests
CME Group reported first-quarter 2025 results, with revenue of $1.6 billion, up 10% from a year earlier, and GAAP diluted earnings per share of $2.62 versus $2.35. Adjusted diluted EPS was $2.80 versus $2.50, and average daily volume reached a record 29.8 million contracts. The release does not include updated forward guidance.
Total revenues of $1,642.3 million for the quarter ended March 31, 2025, up 10% from the prior year
GAAP net income of $956.2 million versus $855.2 million; diluted EPS $2.62 versus $2.35
Adjusted diluted EPS of $2.80 versus $2.50 in the first quarter of 2024
Average daily volume of 29.8 million contracts; cash of $1.6 billion and long-term debt of $3.4 billion at March 31, 2025
CME Group completed a $750 million offering of 4.400% notes due 2030 on March 10, 2025, under its shelf registration. The company plans to use the net proceeds, with cash on hand, to retire its $750 million of 3.00% notes due 2025 and for general corporate purposes. The deal refinances existing debt and adds new debt, with interest payable each March 15 and September 15 beginning September 15, 2025.
Notes: $750 million aggregate principal, 4.400%, due 2030, offered at 99.573% of principal
Proceeds plus cash on hand intended to retire all $750 million of 3.00% notes due 2025
Interest payable March 15 and September 15, starting September 15, 2025; change of control repurchase at 101% of principal
CME Group reported fourth-quarter 2024 revenue of $1.5 billion, up from $1.4 billion a year earlier, with diluted earnings per share of $2.40 versus $2.24. For full-year 2024, revenue was $6.1 billion and diluted earnings per share were $9.67, compared with $8.86 in 2023. On February 6, 2025, the company also declared a first-quarter dividend of $1.25 per share, up 9% from $1.15.
Q4 2024 net income was $875 million, up from $815 million in Q4 2023; diluted EPS was $2.40 versus $2.24.
Q4 2024 adjusted diluted EPS was $2.52, a non-GAAP measure reconciled to GAAP in the release.
Full-year 2024 revenue was $6.1 billion and net income was $3.5 billion.
First-quarter 2025 dividend of $1.25 per share, a 9% increase from $1.15.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CME filing is on SEC EDGAR ↗. 8-K briefs of other companies →